MiNK Therapeutics (NASDAQ:INKT) Trading Up 1.7% – Here’s Why

MiNK Therapeutics, Inc. (NASDAQ:INKT) shares were up 1.7% during trading on Monday . The stock traded as high as $10.62 and last traded at $10.45. Approximately 6,483 shares traded hands during mid-day trading, an increase of 41% from the average daily volume of 4,587 shares. The stock had previously closed at $10.28.

MiNK Therapeutics News Roundup

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: Announced a strategic collaboration with C‑Further to develop a PRAME‑targeted TCR‑engineered iNKT cell therapy for pediatric cancers and will receive roughly $1.1M in non‑dilutive funding to advance the program — this is the core fundamental catalyst behind recent buying. MiNK Therapeutics Announces Collaboration with C‑Further
• Positive Sentiment: Market reaction: shares surged (reports of up to ~80% intraday moves) on the collaboration news, reflecting strong speculative and momentum buying around the pediatric oncology program. MiNK Therapeutics stock soars 80% on C‑Further collaboration
• Neutral Sentiment: Analyst consensus is an average “Hold,” which tempers upside from fundamentals and may limit conviction among institutional investors ahead of upcoming quarterly reporting. MiNK Therapeutics, Inc. Given Average Recommendation of “Hold” by Analysts
• Negative Sentiment: Short‑term technical/flow pressure: headlines suggest today’s pullback is driven by profit‑taking after the big rally, a common follow‑through after rapid gains that can accelerate selling. Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?
• Negative Sentiment: Short interest rose ~18% in February to 37,106 shares (≈1.0% of float) with an 8.6‑day cover ratio — increased shorting can add downward pressure and volatility if momentum reverses.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Trading Down 17.2%

The company has a market capitalization of $52.43 million, a P/E ratio of -3.69 and a beta of 0.35. The firm’s 50 day moving average price is $11.58 and its two-hundred day moving average price is $12.76.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.